These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch. Högl B; Oertel WH; Stiasny-Kolster K; Geisler P; Beneš H; García-Borreguero D; Trenkwalder C; Poewe W; Schollmayer E; Kohnen R BMC Neurol; 2010 Sep; 10():86. PubMed ID: 20920156 [TBL] [Abstract][Full Text] [Related]
4. Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study. Moretti DV; Binetti G; Zanetti O; Frisoni GB Neuropharmacology; 2014 Oct; 85():284-9. PubMed ID: 24915072 [TBL] [Abstract][Full Text] [Related]
5. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome. Bogan RK Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821 [TBL] [Abstract][Full Text] [Related]
6. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome. Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease. Chung SJ; Asgharnejad M; Bauer L; Ramirez F; Jeon B Expert Opin Pharmacother; 2016 Aug; 17(11):1453-61. PubMed ID: 27322571 [TBL] [Abstract][Full Text] [Related]
8. Rotigotine for nocturnal hypokinesia in Parkinson's disease: Quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor. Bhidayasiri R; Sringean J; Chaiwong S; Anan C; Penkeaw N; Leaknok A; Boonpang K; Saksornchai K; Rattanachaisit W; Thanawattano C; Jagota P Parkinsonism Relat Disord; 2017 Nov; 44():124-128. PubMed ID: 28818560 [TBL] [Abstract][Full Text] [Related]
9. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. Antonini A; Bauer L; Dohin E; Oertel WH; Rascol O; Reichmann H; Schmid M; Singh P; Tolosa E; Chaudhuri KR Eur J Neurol; 2015 Oct; 22(10):1400-7. PubMed ID: 26095948 [TBL] [Abstract][Full Text] [Related]
10. Rotigotine Transdermal Patch: A Review in Restless Legs Syndrome. Garnock-Jones KP Drugs; 2016 Jul; 76(10):1031-40. PubMed ID: 27324269 [TBL] [Abstract][Full Text] [Related]
11. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study. Trenkwalder C; Canelo M; Lang M; Schroeder H; Kelling D; Berkels R; Schollmayer E; Heidbrede T; Benes H Sleep Med; 2017 Feb; 30():257-265. PubMed ID: 26896370 [TBL] [Abstract][Full Text] [Related]
12. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice. Ceballos-Baumann A; Häck HJ Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400 [TBL] [Abstract][Full Text] [Related]
13. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Elmer LW; Surmann E; Boroojerdi B; Jankovic J Parkinsonism Relat Disord; 2012 Jun; 18(5):488-93. PubMed ID: 22326237 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany. Stiasny-Kolster K; Berg D; Hofmann WE; Berkels R; Grieger F; Lauterbach T; Schollmayer E; Bachmann CG Sleep Med; 2013 Jun; 14(6):475-81. PubMed ID: 23668924 [TBL] [Abstract][Full Text] [Related]
15. Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study. Zhang ZX; Shang HF; Hu X; Chen S; Zhao Z; Du X; Surmann E; Bauer L; Asgharnejad M Parkinsonism Relat Disord; 2016 Jul; 28():49-55. PubMed ID: 27172830 [TBL] [Abstract][Full Text] [Related]
16. [Local effects of transdermal treatment with rotigotine]. Bermejo PE; Zea MA; Alba-Alcántara L; Ruiz-Huete C Rev Neurol; 2013 Apr; 56(7):359-62. PubMed ID: 23520004 [TBL] [Abstract][Full Text] [Related]
17. Allergic contact dermatitis caused by rotigotine in a transdermal therapeutic system. Raison-Peyron N; Guillot B Contact Dermatitis; 2016 Aug; 75(2):121-2. PubMed ID: 27385523 [No Abstract] [Full Text] [Related]
18. Rotigotine transdermal patch for the treatment of Parkinson's Disease. Perez-Lloret S; Rey MV; Ratti PL; Rascol O Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease. Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880 [TBL] [Abstract][Full Text] [Related]
20. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome. Boroojerdi B; Wolff HM; Braun M; Scheller DK Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]